From the opinion pages of the Wall Street Journal, this is Potomac Watch.

Americans love their medicines, but they don't seem to always like the companies that make them.

That's all the opening politicians need to attack drug companies and to try to control their prices, among other things.

Democrats stated under Joe Biden, and now President Trump is getting into the act.

What does that mean for the future of drug innovation, for future cures, for rare and troubling

diseases, and what you pay at the local pharmacy. That's our subject on the

Potomac Watch today. I'm Paul as you go here at the Daily podcast of the Wall Street Journal,

and I'm here with Kate, Batchel, Odell, and Alicia Finley. All right, you journalists who cover

this health care industry, I'm going to go down a list here of things

the Trump administration is doing. Now, this is a Republican administration, supposedly it likes

business, right? At least that's the accusation, the favor business. But let me go through a list of

what the administration is doing or wants to do on drug companies, okay? Imposed price controls on

drugs sold in the U.S. make sure that those companies sell

their drugs at the lowest price.

They also sell them in the developed world.

That's not the average price.

It's the lowest price, okay?

100% tariff threat on imported drugs, and a lot of companies make generics in particular overseas, 100%

tariff on those, reduced and slower approvals of drugs at the Food and Drug Administration,

especially for drugs that want an accelerated approval basis for rare diseases, and a de facto ban on advertising by drug companies

on television. You know, those ubiquitous waygovi ads, which we all hate, but nonetheless

are telling people that these medicines are available for people. Now, this is a Republican

...